Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial-Reference-Cited by-同舟云学术

Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial

Published:2022-08-23 Issue:10 Volume:36 Page:2443-2452
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Yen Ryan,Grasedieck Sarah^ORCID,Wu Andrew^ORCID,Lin Hanyang,Su Jiechuang,Rothe Katharina,Nakamoto Helen,Forrest Donna L.,Eaves Connie J.^ORCID,Jiang Xiaoyan^ORCID

Funder

Canadian Cancer Society Research Institute

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-022-01680-4.pdf

Reference56 articles.

1. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290–3.

2. Holyoake TL, Vetrie D. The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood 2017;129:1595–606.

3. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl J Med. 2006;355:2408–17.